ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1383

Proteomics and Machine Learning Accurately Predict Clinical Response to Etanercept Therapy in Patients with Rheumatoid Arthritis
Abstract Number: 2564

Providing Optimal and Equitable Osteoporosis Treatment Using a Programmatic Approach -A 20 Year Longitudinal Study
Abstract Number: 2332

PsAID12 Thresholds Defining Disease Impact Severity in Psoriatic Arthritis Developed in an Observational Setting Showed Higher Sensitivity but Lower Specificity Than Those Developed in a Randomized Controlled Trial Setting
Abstract Number: 0156

Psoriasis and Psoriatic Arthritis Are Independent Risk Factors for Non-Fatal Cardiovascular Admissions in Transition-Age Young Adults
Abstract Number: 0067

Psoriasis Patients at Risk for Psoriatic Arthritis Have Increased Levels of Circulating Pro-migratory Dendritic Cells
Abstract Number: 1883

Psoriatic Arthritis Flare Incidence, Definitions and Risk Factors: A Systematic Review
Abstract Number: 1528

Pulmonary Arterial Hypertension in Systemic Lupus Erythematosus: National Inpatient Sample Analysis
Abstract Number: 0993

Pulmonary Complications and Mortality Trends in Rheumatoid Arthritis Patients Aged 65 and Older in the United States: A CDC WONDER Database Analysis
Abstract Number: 2234

Pulmonary Damage Biomarkers and Progression of Rheumatoid Arthritis-associated Interstitial Lung Disease in a Prospective Longitudinal Cohort
Abstract Number: 1689

Pulmonary Function Test Reference Equations May Drive Inequitable Classification of Restrictive Lung Disease Severity in Systemic Sclerosis
Abstract Number: 1140

Pulmonary Hypertension in Hospitalized Patients with Dermatomyositis & Polymyositis: A Nationwide Cohort Analysis
Abstract Number: 1242

Qualitative Patient Interview Study in Patients with Systemic Lupus Erythematosus to Assess Patient Perception of Fatigue and Skin-Related Symptoms
Abstract Number: 1250

Qualitative Study on Patient-Reported Outcome Measures in Patients with Sjögren’s Disease
Abstract Number: 0426

Quality Improvement Initiative to Increase Contraception Screening and Documentation for Reproductive-Aged Women Prescribed Teratogenic Medications in an Academic Rheumatology Center
Abstract Number: 2622

Quality of Care for Childhood-Onset Lupus Nephritis: Suboptimal Completion of Disease Activity Monitoring

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].